Compelling Indications Should be Listed for Individual Beta-Blockers (Due to Diversity), Not for the Whole Class

Curr Vasc Pharmacol. 2021;19(4):343-346. doi: 10.2174/1570161118666200518113833.

Authors

Goran Koracevic¹, Sladjana Micic², Milovan Stojanovic³, Dragan Lovic⁴, Dragan Simic⁵, Mirko Colic⁶, Maja Koracevic², Aleksandar Stojkovic¹, Milenko Paunovic⁷

Affiliations

¹ Department for Cardiovascular Diseases, Clinical Center Nis, Nis, Serbia.
² Faculty of Medicine, University of Nis, Nis, Serbia.
³ Institute for Treatment and Rehabilitation Niska Banja, Nis, Serbia.
⁴ Clinic for Internal Diseases Intermedica, Nis, Serbia.
⁵ Clinical Center of Serbia, Department of Cardiology, Belgrade, Serbia.
⁶ Department of Cardiology, Dedinje Cardiovascular Institute, Belgrade, Serbia.
⁷ Health Center Kladovo, Kladovo, Serbia.

PMID: 32418526
DOI: 10.2174/1570161118666200518113833

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adrenergic beta-Antagonists* / classification
Adrenergic beta-Antagonists* / therapeutic use
Antihypertensive Agents / classification
Antihypertensive Agents / therapeutic use
Humans
Hypertension* / drug therapy

Substances

Adrenergic beta-Antagonists
Antihypertensive Agents